Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone

被引：0
|
作者：
Paiva, Bruno [1 ]
Lopez-Corral, Lucia [1 ]
Vidriales, Maria-Belen [1 ]
Sanchez Abarca, Luis Ignacio [1 ]
Hernandez, Miguel T. [2 ]
Bargay, Joan [3 ]
De La Rubia, Javier [4 ]
Giraldo, Pilar [5 ]
Teruel, Ana-Isabel [6 ]
Rosinol, Laura [7 ]
Oriol, Albert [8 ]
Hernandez, Jose [9 ]
de Arriba, Felipe [10 ]
Esteves, Graca [11 ]
Perez Simon, Jose Antonio [1 ]
Mateos, Maria-Victoria [1 ]
San Miguel, Jesus F. [12 ]
机构：
[1] Hosp Univ Salamanca, Salamanca, Spain
[2] Hosp Univ Canarias, Serv Hematol Clin, Tenerife, Spain
[3] CETLAM Cooperat Grp, Palma de Mallorca, Spain
[4] Hosp La Fe, E-46009 Valencia, Spain
[5] Hosp Miguel Servet, Zaragoza, Spain
[6] Hosp Clin Univ Valencia, Valencia, Spain
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] CETLAM Cooperat Grp, Badalona, Spain
[9] Hosp Gen Segovia, Segovia, Spain
[10] Hosp Morales Messeguer, Murcia, Spain
[11] Hosp Santa Maria, Lisbon, Portugal
[12] Hosp Clin Univ, Salamanca, Spain
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：794 / 795
页数：2
相关论文
共 50 条
  • [31] High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
    G Bianchi
    R A Kyle
    D R Larson
    T E Witzig
    S Kumar
    A Dispenzieri
    W G Morice
    S V Rajkumar
    Leukemia, 2013, 27 : 680 - 685
  • [32] The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
    Hill, Elizabeth
    Korde, Neha
    Morrison, Candis
    Dew, Alexander
    Carpenter, Ashley
    Epstein, Monica
    Lu, Crystal
    Choyke, Peter
    Mena, Esther
    Lindenberg, Liza
    Landgren, Ola
    Kazandjian, Dickran
    BLOOD, 2020, 136
  • [33] Peripheral blood circulating multiple myeloma cells (CMMCs) correlate with disease burden and can be used to characterize high-risk cytogenetics in newly diagnosed and smoldering myeloma
    Foulk, Brad
    Schaffer, Mike
    Gross, Steve
    Rao, Chandra
    Smirnov, Denis
    Chaturvedi, Shalini
    Reddy, Manjula
    Repollet, Madeline
    Rojas, Claudia
    Auclair, Daniel
    DeRome, Mary
    Weiss, Brendan
    Sasser, A. Kate
    CANCER RESEARCH, 2016, 76
  • [34] High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
    Bianchi, G.
    Kyle, R. A.
    Larson, D. R.
    Witzig, T. E.
    Kumar, S.
    Dispenzieri, A.
    Morice, W. G.
    Rajkumar, S. V.
    LEUKEMIA, 2013, 27 (03) : 680 - 685
  • [35] Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis
    Mateos, Maria-Victoria
    Hernandez, Miguel-T
    Giraldo, Pilar
    De La Rubia, Javier
    De Arriba, Felipe
    Lopez-Corral, Lucia
    Rosinol, Laura
    Paiva, Bruno
    Palomera, Luis
    Bargay, Joan
    Oriol, Albert
    Prosper, Felipe
    Lopez, Javier, Sr.
    Arguinano, Jose-Maria
    Quintana, Nuria
    Garcia, Jose Luis
    Blade, Joan
    Lahuerta, Juan Jose
    Miguel, Jesus San
    BLOOD, 2016, 128 (22)
  • [36] A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
    Patel, Roshani
    Bhaskarla, Amrit
    Gordon, Max J.
    Emanuel, Michael
    Colon, Dana I. Delgado
    Wang, Hao-Wei
    Yuan, Constance M.
    Lindenberg, Liza
    Mena, Esther
    Turkbey, Baris
    Micheletti, Nick
    Yee, Laura M.
    Patel, Nisha
    Maric, Irina
    Braylan, Raul C.
    Calvo, Katherine R.
    Staudt, Louis M.
    Young, Ryan M.
    Roschewski, Mark
    Kazandjian, Dickran
    Hill, Elizabeth
    BLOOD, 2024, 144 : 7059 - 7060
  • [37] Characterization of γδ regulatory T cells from peripheral blood in patients with multiple myeloma
    Ma, Yongyong
    Lei, Huyi
    Tan, Jie
    Xuan, Li
    Wu, Xiuli
    Liu, Qifa
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 480 (04) : 594 - 601
  • [38] ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
    Ghobrial, Irene
    Rodriguez-Otero, Paula
    Koh, Youngil
    Martinez-Lopez, Joaquin
    Parmar, Gurdeep
    Prince, Miles
    Quach, Hang
    de la Rubia, Javier
    Hermansen, Emil
    Hungria, Vania
    Besisik, Sevgi Kalayoglu
    Kim, Jin Seok
    Leleu, Xavier
    Peceliunas, Valdas
    Schjesvold, Fredrik
    Dubin, Franck
    Devisme, Christine
    Lepine, Lucie
    Mace, Sandrine
    Oprea, Corina
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S109 - S110
  • [39] BLOOD STEM-CELLS AUTOGRAFTS IN PATIENTS WITH HIGH-RISK MULTIPLE-MYELOMA
    MONTUORO, A
    DEROSA, L
    ZOLI, V
    PANDOLFI, A
    COSSUTTA, M
    LANTI, T
    DELAURENZI, A
    HAEMATOLOGICA, 1990, 75 : 65 - 69
  • [40] ANALYSIS OF INCIDENCE OF THROMBOSIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE-DEXAMETHASONE IN OUR CENTER. THE INFLUENCE OF RISK FACTORS
    Garcia Fortes, M.
    Caparros Miranda, I. S.
    Gonzalez Fernandez, A.
    Fernandez Fernandez, A.
    Rivas Luque, M.
    Cabrera Ruiz, F.
    Garcia Sanchez, R.
    Ruiz Arredondo, J. J.
    HAEMATOLOGICA, 2015, 100 : 100 - 101
12345